Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03382106 · ClinicalTrials.gov registry record · Phase 4
Smoking Cessation and Functional CT Assessment
A Phase 4 study, sponsored by Eric A. Hoffman.
- Completed
- Registry status
- Phase 4
- Development phase
- 162
- Enrollment target
NCT03382106 is a Phase 4 study that has completed, run by Eric A. Hoffman. The registered enrollment target is 162 participants.
The verdict
NCT03382106, a Phase 4 study, has completed, sponsored by Eric A. Hoffman.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 162 participants
- Enrollment target
Study Summary
The investigators will study the effect of pulmonary arterial vasodilation to see if it eliminates indices of persistent lung injury in smokers that are susceptible to emphysema.
Interventions
- DRUG Placebo Oral Tablet
- DRUG Sildenafil 20 MG
- DIAGNOSTIC_TEST Pulse wave velocity
- DIAGNOSTIC_TEST Carotid artery compliance and stiffness
- DIAGNOSTIC_TEST Pressure wave reflection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2018-03-19 |
| Est. Completion | 2024-09-24 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03382106
The ClinicalTrials.gov registry entry for NCT03382106 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eric A. Hoffman, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo Oral Tablet is the first listed.
NCT03382106 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03382106 about?
NCT03382106 is a clinical study titled "Smoking Cessation and Functional CT Assessment". The investigators will study the effect of pulmonary arterial vasodilation to see if it eliminates indices of persistent lung injury in smokers that are susceptible to emphysema.
What is the current status of trial NCT03382106?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 162 participants. The study started on 2018-03-19. Estimated completion is 2024-09-24.
What interventions are being tested in trial NCT03382106?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Sildenafil 20 MG (DRUG), Pulse wave velocity (DIAGNOSTIC_TEST), Carotid artery compliance and stiffness (DIAGNOSTIC_TEST), Pressure wave reflection (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03382106?
This trial is sponsored by Eric A. Hoffman, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.